Designing a multi-epitope influenza vaccine: an immunoinformatics approach.
Influenza Vaccines
/ immunology
Humans
Molecular Docking Simulation
Computational Biology
/ methods
Molecular Dynamics Simulation
Influenza, Human
/ prevention & control
Epitopes, T-Lymphocyte
/ immunology
Epitopes, B-Lymphocyte
/ immunology
T-Lymphocytes, Cytotoxic
/ immunology
Influenza A virus
/ immunology
Epitopes
/ immunology
Immunoinformatics
Immunoinformatics
Influenza
Molecular dynamics simulation
Multi-epitope
Phage display vaccine
Reverse vaccinology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
02
05
2024
accepted:
26
09
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
Influenza continues to be one of the top public health problems since it creates annual epidemics and can start a worldwide pandemic. The virus's rapid evolution allows the virus to evade the host defense, and then seasonal vaccines need to be reformulated nearly annually. However, it takes almost half a year for the influenza vaccine to become accessible. This delay is especially concerning in the event of a pandemic breakout. By producing the vaccine through reverse vaccinology and phage display vaccines, this time can be reduced. In this study, epitopes of B lymphocytes, cytotoxic T lymphocytes, and helper T lymphocytes of HA, NA, NP, and M2 proteins from two strains of Influenza A were anticipated. We found two proper epitopes (ASFIYNGRL and LHLILWITDRLFFKC) in Influenza virus proteins for CTL and HTL cells, respectively. Optimal epitopes and linkers in silico were cloned into the N-terminal end of M13 protein III (pIII) to create a multi-epitope-pIII construct, i.e., phage display vaccine. Also, prediction of tertiary structure, molecular docking, molecular dynamics simulation, and immune simulation were performed and showed that the designed multi-epitope vaccine can bind to the receptors and stimulate the immune system response.
Identifiants
pubmed: 39455641
doi: 10.1038/s41598-024-74438-w
pii: 10.1038/s41598-024-74438-w
doi:
Substances chimiques
Influenza Vaccines
0
Epitopes, T-Lymphocyte
0
Epitopes, B-Lymphocyte
0
Epitopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25382Informations de copyright
© 2024. The Author(s).
Références
1. Cox, R. J., Brokstad, K. A. & Ogra, P. Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines. Scand. J. Immunol. 59, 1–15 (2004).
2. Influenza (Seasonal). https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal).
3. Amorij, J.-P., Huckriede, A., Wilschut, J., Frijlink, H. W. & Hinrichs, W. L. J. Development of Stable Influenza Vaccine Powder Formulations: Challenges and Possibilities. Pharm. Res. 25, 1256 (2008).
4. Treanor, J. J. Influenza Vaccination. N. Engl. J. Med. 375, 1261–1268 (2016).
5. Ben-Yedidia, T. & Arnon, R. Epitope-based vaccine against influenza. Expert Rev. Vaccines. 6, 939–948 (2007).
6. Bouvier, N. M. & Palese, P. The biology of influenza viruses. Vaccine. 26, D49–D53 (2008).
7. Parrish, C. R. & Kawaoka, Y. The origins of new pandemic viruses: The Acquisition of New Host Ranges by Canine Parvovirus and Influenza A Viruses. Annu. Rev. Microbiol. 59, 553–586 (2005).
8. CDC. Types of Influenza Viruses. Centers for Disease Control and Prevention https://www.cdc.gov/flu/about/viruses/types.htm (2023).
9. Medina, R. A. & García-Sastre, A. Influenza A viruses: new research developments. Nat. Rev. Microbiol. 9, 590–603 (2011).
10. Gerdil, C. The annual production cycle for influenza vaccine. Vaccine. 21, 1776–1779 (2003).
11. Valenciano, M. et al. Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study. PLOS Med. 8, e1000388 (2011).
12. Lu, Y., Welsh, J. P. & Swartz, J. R. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc. Natl. Acad. Sci. U. S. A. 111, 125–130 (2014).
13. Mora, M., Veggi, D., Santini, L., Pizza, M. & Rappuoli, R. Reverse vaccinology. Drug Discov. Today. 8, 459–464 (2003).
14. Rawal, K. et al. Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. Sci. Rep. 11, 17626 (2021).
15. Khalid, H. & Ashfaq, U. A. Exploring HCV genome to construct multi-epitope based subunit vaccine to battle HCV infection: Immunoinformatics based approach. J. Biomed. Inform. 108, 103498 (2020).
16. De Filette, M. et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine. 26, 6503–6507 (2008).
17. Neirynck, S. et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5, 1157–1163 (1999).
18. Sanami, S. et al. Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches. Sci. Rep. 11, 12397 (2021).
19. Singh, A., Thakur, M., Sharma, L. K. & Chandra, K. Designing a multi-epitope peptide based vaccine against SARS-CoV-2. Sci. Rep. 10, 16219 (2020).
20. Eliasson, D. G. et al. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. Vaccine. 29, 3951–3961 (2011).
21. Eliasson, D. G. et al. CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine. Vaccine. 26, 1243–1252 (2008).
22. Nain, Z., Karim, M. M., Sen, M. K. & Adhikari, U. K. Structural basis and designing of peptide vaccine using PE-PGRS family protein of Mycobacterium ulcerans—An integrated vaccinomics approach. Mol. Immunol. 120, 146–163 (2020).
23. Reese, K. A. et al. A Novel Lactococcal Vaccine Expressing a Peptide from the M2 Antigen of H5N2 Highly Pathogenic Avian Influenza A Virus Prolongs Survival of Vaccinated Chickens. Vet. Med. Int. 2013, 316926 (2013).
24. Hashemi, H. et al. Immunization with M2e-Displaying T7 Bacteriophage Nanoparticles Protects against Influenza A Virus Challenge. PLoS ONE. 7, e45765 (2012).
25. Deng, L. et al. Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages. PLoS ONE. 10, e0126650 (2015).
26. González-Mora, A., Hernández-Pérez, J., Iqbal, H. M. N., Rito-Palomares, M. & Benavides, J. Bacteriophage-Based Vaccines: A Potent Approach for Antigen Delivery. Vaccines. 8, 504 (2020).
27. Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 228, 1315–1317 (1985).
28. Marvin, D. A., Hale, R. D., Nave, C. & Helmer-Citterich, M. Molecular models and structural comparisons of native and mutant class I filamentous bacteriophages Ff (fd, f1, M13), If1 and IKe. J. Mol. Biol. 235, 260–286 (1994).
29. Scott, J. K. & Smith, G. P. Searching for peptide ligands with an epitope library. Science. 249, 386–390 (1990).
30. Nicastro, J., Sheldon, K. & Slavcev, R. A. Bacteriophage lambda display systems: developments and applications. Appl. Microbiol. Biotechnol. 98, 2853–2866 (2014).
31. Samoylova, T. I. et al. Infective and inactivated filamentous phage as carriers for immunogenic peptides. J. Virol. Methods. 183, 63–68 (2012).
32. Salmond, G. P. C. & Fineran, P. C. A century of the phage: past, present and future. Nat. Rev. Microbiol. 13, 777–786 (2015).
33. Loc-Carrillo, C. & Abedon, S. T. Pros and cons of phage therapy. Bacteriophage. 1, 111–114 (2011).
34. Prisco, A. & De Berardinis, P. Filamentous Bacteriophage Fd as an Antigen Delivery System in Vaccination. Int. J. Mol. Sci. 13, 5179–5194 (2012).
35. Lavie, V. et al. EFRH–Phage Immunization of Alzheimer’s Disease Animal Model Improves Behavioral Performance in Morris Water Maze Trials. J. Mol. Neurosci. 24, 105–114 (2004).
36. Aghebati-Maleki, L. et al. Phage display as a promising approach for vaccine development. J. Biomed. Sci. 23, 66 (2016).
37. di Marzo Veronese, F., Willis, A. E., Boyer-Thompson, C., Appella, E. & Perham, R. N. Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage. The V3 loop of HIV-1 gp120. J. Mol. Biol. 243, 167–172 (1994).
38. van Houten, N. E., Zwick, M. B., Menendez, A. & Scott, J. K. Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide. Vaccine. 24, 4188–4200 (2006).
39. Yip, Y. L., Smith, G. & Ward, R. L. Comparison of phage pIII, pVIII and GST as carrier proteins for peptide immunisation in Balb/c mice. Immunol. Lett. 79, 197–202 (2001).
40. Saha, S. & Raghava, G. P. S. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins. 65, 40–48 (2006).
41. Saha, S. & Raghava, G. P. S. BcePred: Prediction of Continuous B-Cell Epitopes in Antigenic Sequences Using Physico-chemical Properties. in Artificial Immune Systems (eds. Nicosia, G., Cutello, V., Bentley, P. J. & Timmis, J.) 197–204 (Springer, Berlin, Heidelberg, 2004). https://doi.org/10.1007/978-3-540-30220-9_16 .
42. Dimitrov, I., Bangov, I., Flower, D. R. & Doytchinova, I. AllerTOP v.2—a server for in silico prediction of allergens. J. Mol. Model. 20, 2278 (2014).
43. Singh, H. & Raghava, G. P. S. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinforma. Oxf. Engl. 19, 1009–1014 (2003).
44. Doytchinova, I. A., Guan, P. & Flower, D. R. EpiJen: a server for multistep T cell epitope prediction. BMC Bioinformatics. 7, 131 (2006).
45. Nielsen, M. et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. Publ. Protein Soc. 12, 1007–1017 (2003).
46. Andreatta, M. & Nielsen, M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 32, 511–517 (2016).
47. Larsen, M. V. et al. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics. 8, 424 (2007).
48. Jensen, K. K. et al. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 154, 394–406 (2018).
49. Dhanda, S. K., Gupta, S., Vir, P. & Raghava, G. P. S. Prediction of IL4 inducing peptides. Clin. Dev. Immunol. 2013, 263952 (2013).
50. Dhanda, S. K., Vir, P. & Raghava, G. P. Designing of interferon-gamma inducing MHC class-II binders. Biol. Direct. 8, 30 (2013).
51. Magnan, C. N. et al. High-throughput prediction of protein antigenicity using protein microarray data. Bioinforma. Oxf. Engl. 26, 2936–2943 (2010).
52. Saha, S. & Raghava, G. P. S. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res. 34, W202-209 (2006).
53. Sippl, M. J. Recognition of errors in three-dimensional structures of proteins. Proteins. 17, 355–362 (1993).
54. Wiederstein, M. & Sippl, M. J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 35, W407–W410 (2007).
55. Gao, J., Wang, Y., Liu, Z. & Wang, Z. Phage display and its application in vaccine design. Ann. Microbiol. 60, 13–19 (2010).
56. Hashemi, H., Bamdad, T., Jamali, A., Pouyanfard, S. & Mohammadi, M. G. Evaluation of humoral and cellular immune responses against HSV-1 using genetic immunization by filamentous phage particles: A comparative approach to conventional DNA vaccine. J. Virol. Methods. 163, 440–444 (2010).
57. Van Belleghem, J. D., Dąbrowska, K., Vaneechoutte, M., Barr, J. J. & Bollyky, P. L. Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System. Viruses. 11, 10 (2019).
58. Fang, J. et al. The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model. Vaccine. 23, 4860–4866 (2005).
59. Sartorius, R. et al. Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response. EMBO Mol. Med. 7, 973–988 (2015).
60. Ohto, U. et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature. 520, 702–705 (2015).
61. Fukui, R. et al. Cleavage of Toll-Like Receptor 9 Ectodomain Is Required for In Vivo Responses to Single Strand DNA. Front. Immunol. 9, (2018).
62. Ohto, U. et al. Toll-like Receptor 9 Contains Two DNA Binding Sites that Function Cooperatively to Promote Receptor Dimerization and Activation. Immunity. 48, 649–658.e4 (2018).
63. Ishida, H., Ohto, U., Shibata, T., Miyake, K. & Shimizu, T. Structural basis for species-specific activation of mouse Toll-like receptor 9. FEBS Lett. 592, 2636–2646 (2018).
64. Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 1–2, 19–25 (2015).
65. Barkhordari, A., Mahnam, K. & Mirmohammad-Sadeghi, H. Designing a new bispecific tandem single-chain variable fragment antibody against tumor necrosis factor-α and interleukin-23 using in silico studies for the treatment of rheumatoid arthritis. J. Mol. Model. 26, 225 (2020).
66. Néron, B. et al. Mobyle: a new full web bioinformatics framework. Bioinforma. Oxf. Engl. 25, 3005–3011 (2009).
67. Alland, C. et al. RPBS: a web resource for structural bioinformatics. Nucleic Acids Res. 33, W44–W49 (2005).
68. Li, S., Olson, W. K. & Lu, X.-J. Web 3DNA 2.0 for the analysis, visualization, and modeling of 3D nucleic acid structures. Nucleic Acids Res. 47, W26–W34 (2019).
69. Honorato, R. V. et al. Structural Biology in the Clouds: The WeNMR-EOSC Ecosystem. Front. Mol. Biosci. 8, 729513 (2021).
70. van Zundert, G. C. P. et al. The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes. J. Mol. Biol. 428, 720–725 (2016).
71. Kumari, R., Kumar, R., Open Source Drug Discovery Consortium & Lynn, A. g_mmpbsa–a GROMACS tool for high-throughput MM-PBSA calculations. J. Chem. Inf. Model. 54, 1951–1962 (2014).
72. Padilla-Quirarte, H. O., Lopez-Guerrero, D. V., Gutierrez-Xicotencatl, L. & Esquivel-Guadarrama, F. Protective Antibodies Against Influenza Proteins. Front. Immunol. 10, 1677 (2019).
73. Paules, C. I., Sullivan, S. G., Subbarao, K. & Fauci, A. S. Chasing Seasonal Influenza - The Need for a Universal Influenza Vaccine. N. Engl. J. Med. 378, 7–9 (2018).
74. Raymond, D. D. et al. Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. Proc. Natl. Acad. Sci. 115, 168–173 (2018).
75. Joyce, M. G. et al. Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell. 166, 609–623 (2016).
76. Zalewska-Piątek, B. & Piątek, R. Bacteriophages as Potential Tools for Use in Antimicrobial Therapy and Vaccine Development. Pharmaceuticals. 14, 331 (2021).
77. Gupta, N. & Kumar, A. Designing an efficient multi-epitope vaccine against Campylobacter jejuni using immunoinformatics and reverse vaccinology approach. Microb. Pathog. 147, 104398 (2020).
78. Forouharmehr, A. Engineering an efficient poly-epitope vaccine against Toxoplasma gondii infection: A computational vaccinology study. Microb. Pathog. 152, 104646 (2021).
79. Tahir ul Qamar, M. et al. Designing multi-epitope vaccine against Staphylococcus aureus by employing subtractive proteomics, reverse vaccinology and immuno-informatics approaches. Comput. Biol. Med. 132, 104389 (2021).
80. Safavi, A., Kefayat, A., Mahdevar, E., Abiri, A. & Ghahremani, F. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine. 38, 7612–7628 (2020).
81. Sanami, S. et al. Exploring SARS-COV-2 structural proteins to design a multi-epitope vaccine using immunoinformatics approach: An in silico study. Comput. Biol. Med. 133, 104390 (2021).
82. Bao, Q. et al. Phage-based vaccines. Adv. Drug Deliv. Rev. 145, 40–56 (2019).
83. Hess, K. L. & Jewell, C. M. Phage display as a tool for vaccine and immunotherapy development. Bioeng. Transl. Med. 5, e10142 (2019).
84. Iwagami, Y. et al. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma. Heliyon. 3, e00407 (2017).
85. Morales, J. et al. Inexpensive anti-cysticercosis vaccine: S3Pvac expressed in heat inactivated M13 filamentous phage proves effective against naturally acquired Taenia solium porcine cysticercosis. Vaccine. 26, 2899–2905 (2008).
86. Bastien, N., Trudel, M. & Simard, C. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus. Virology. 234, 118–122 (1997).
87. Wan, Y. et al. Induction of hepatitis B virus-specific cytotoxic T lymphocytes response in vivo by filamentous phage display vaccine. Vaccine. 19, 2918–2923 (2001).
88. Stoloff, G. A. & Caparros-Wanderley, W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur. J. Immunol. 37, 2441–2449 (2007).
89. Staneková, Z. & Varečková, E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol. J. 7, 351 (2010).
90. Maleki, A., Russo, G., Parasiliti Palumbo, G. A. & Pappalardo, F. In silico design of recombinant multi-epitope vaccine against influenza A virus. BMC Bioinformatics. 22, 617 (2022).
91. Kanse, S. et al. Designing a Multi-Epitope Subunit Vaccine against VP1 Major Coat Protein of JC Polyomavirus. Vaccines. 11, 1182 (2023).
92. Jiang, F. et al. PP19128R, a Multiepitope Vaccine Designed to Prevent Latent Tuberculosis Infection, Induced Immune Responses In Silico and In Vitro Assays. Vaccines. 11, 856 (2023).
93. Khamjan, N. A., Lohani, M., Khan, M. F., Khan, S. & Algaissi, A. Immunoinformatics Strategy to Develop a Novel Universal Multiple Epitope-Based COVID-19 Vaccine. Vaccines. 11, 1090 (2023).
94. Wilkins, M. R. et al. Protein identification and analysis tools in the ExPASy server. Methods Mol. Biol. Clifton NJ. 112, 531–552 (1999).
95. Sarkar, B., Ullah, M. A. & Araf, Y. A systematic and reverse vaccinology approach to design novel subunit vaccines against Dengue virus type-1 (DENV-1) and human Papillomavirus-16 (HPV-16). Inform. Med. Unlocked. 19, 100343 (2020).
96. Ashfaq, U. A. et al. Rational design of multi epitope-based subunit vaccine by exploring MERS-COV proteome: Reverse vaccinology and molecular docking approach. PloS ONE. 16, e0245072 (2021).